# A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

> **NCT07729462** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 400 (estimated)

## Conditions studied

- Preventive Treatment of Migraine

## Interventions

- **DRUG:** Rimegepant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07729462
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-26
- **Primary completion:** 2028-10-21
- **Final completion:** 2029-01-19
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729462, "A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07729462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*